ABSTRACT
Bullet Points


Cirrhotic patients who achieve an SVR to anti-HCV regimens should remain on regular HCC
surveillance since it has been demonstrated that the risk of liver cancer is not fully abrogated by viral eradication  Whether regression of cirrhosis following an SVR may prevent liver-related complications is still unknown  In our cohort of cirrhotic patients who achieved an SVR through IFN-based regimens, HCC occurred at low rates independently on post-SVR cirrhosis regression  Neither clinical parameters, post-SVR histological features or non-invasive tests were able to predict the occurrence of HCC in our cohort of selected patients
INTRODUCTION
The advent of safe and effective direct-acting antivirals (DAA) has revolutionized treatment of chronic hepatitis C raising the bar of virus eradication above 90% in hepatitis C virus (HCV) cirrhotics who have longer been the hardest patients to be cured with interferon (IFN) 1 . In the IFN era, patients with advanced liver disease who achieved HCV eradication appeared to be partially protected against the risk of clinical decompensation and hepatocellular carcinoma (HCC)
development. The identification of risk factors associated with HCC development in HCV cirrhotics with a sustained virological response (SVR) could allow to design individualized surveillance schedules, hence containing healthcare costs. In a single-center study in France, end-stage complications of HCV were fully prevented in the subgroup of SVR patients with histologically documented regressed cirrhosis 2 . Indeed, cirrhosis regression was not infrequent among IFNresponders, with rates from 24% to 100% 2- 16 .
Mitigating the impact of cirrhosis regression in SVR patients, however, is suboptimal accuracy of liver biopsy (LB) to establish cirrhosis regression, owing to the 25% risk of fibrosis misclassification of small liver tissue cores 17 . This coupled with the fact that the French study correlated the histological regression of cirrhosis with combined endpoints including liver failure, bleeding and HCC, prompted us to prospectively evaluate the clinical outcome of a cohort of 38 cirrhotics, 23 (61%) of whom with histological cirrhosis regression 5 years after the achievement of an SVR 18 . Regressors and non regressors were then subjected to surveillance for HCC with 6-month abdominal ultrasound (US).
MATERIAL AND METHODS
Patient population
This is a long-term follow-up study of previously published Italian-French cooperative study conducted on 38 HCV cirrhotics who underwent paired LB, before and after the achievement of an SVR to IFN-based regimens 18 . All patients were prospectively followed-up after post-SVR LB (baseline); hepatitis B virus (HBV) or human immunodeficiency virus (HIV) coinfections as well as alcohol consumption, which were previously excluded 18 , were confirmed during follow-up. 
Biochemical assays
The following normal values were used: alanine aminotransferase (ALT) < 19 U/l for females and <30 U/l for males 19 ; γglutamil-transferase (γGT) <36 U/l for females and <60 U/l for males; cholesterol <200 mg/dL, high density lipoprotein (HDL) cholesterol >60 mg/dL; triglycerides < 150 mg/dL; alpha-fetoprotein (αFP) <7 μg/ml. 
Histological assessment
Study endpoints
The primary endpoint of the study was the relationship between post-SVR cirrhosis regression and After LB, all patients were adherent to 6-month surveillance, and were followed-up for 86 months, without any differences between patients with and without cirrhosis regression [88 (74-96) vs. 83 (30-95), p=0.52]. During follow-up, most of them showed persistently normal values of both ALT and γGT (71% and 68%, respectively).
Liver-related events
No episodes of clinical decompensation or GI-bleeding were recorded, whilst HCC developed in 5 (13%) patients. Median time to HCC development was 79 (7-88) months. The 8-year cumulative probability of HCC was 17% (95% CI: 7% -39%), with an annual estimated incidence rate of 1.2%
( Figure 1A ). were close to statistical significance (Table 3) .
Patients who did develop an HCC were also similar to those who did not in most of the baseline histological features, as assessed at the time of post-SVR LB. In patients who developed HCC advanced stages of residual fibrosis were frequent (p=0.06) although the prevalence of cirrhosis was similar in patients with or without HCC (40% vs. 40%, p= 1.0) ( Table 4 ). The 8-year cumulative probability of HCC was similar in patients with or without cirrhosis regression (p=0.88). However, the two patients with residual cirrhosis developed HCC earlier than those who achieved cirrhosis regression (7 and 27 months vs. 79, 80 and 88 months from LB) ( Figure 1B ). In addition, no differences were observed in terms of steatosis, residual collagen content or improvement in the area of fibrosis as compared to pre-treatment values. Similarly, immunohistochemistry did not differ between the two groups.
Baseline LSM did not differ among patients who subsequently developed or not an HCC (12.6 kPa vs. 9.8 kPa, p=0.78) ( Table 2) . Nevertheless, although we did not observe any difference for most of the NITs according to the presence of HCC, patients who developed liver cancer had higher post-SVR values of Lok Index (p=0.05), whilst Forns Score (p=0.09) and PLF (p=0.06) were close to statistical significance (Table 5) . At univariate analysis, the following NITs were associated with an increased risk of HCC: Forns Score > 6.9 (p=0.039), Lok Index > 0.5 (p=0.046) and PLF > 2.98 (p=0.016) ( Table 3) .
Non-liver related events
Extra-hepatic malignancies were the only non-liver related events recorded in 3 (7.8%) patients, all without HCC. Uterine cancer, lung cancer and rectal cancer developed after 71 (51-76) months from baseline. In conclusion, the finding that HCC developed also in SVR patients with cirrhosis regression (F3) greatly attenuates the need for refining the management of SVR patients in relation to residual liver fibrosis. The fact that regressed patients developed HCC later than non regressors deserves attention, as it might suggest the presence of causes of liver disease progression other than HCV.
Survival
However, two out of three patients with a liver cancer showed regression to METAVIR F3 in the absence of any additional cause of liver disease. We wish to think that the risk of HCC in such regressors is the consequence of long lasting exposure of liver cells to direct and indirect carcinogenetic effects of HCV, as clearly documented in more than one experimental study 41 .
Our finding that patient survival was not influenced by either residual fibrosis stage or HCC occurrence (one patient died of non-liver related complication, only) is in line with a recently published multicentre study in Italy 30,31 where SVR cirrhotics showed comparable survival rates as the general population 31 .
We acknowledge that our study was to some extent weakened by the strict selection criteria we adopted; yet, at the same time it provides robust information to refine surveillance of SVR patients,
i.e. not to interrupt surveillance in SVR patients with an initial diagnosis of cirrhosis.
In conclusion, our finding that the risk of liver cancer among SVR cirrhotics was not fully Forns Score* > 6. 
